Category: Eli Lilly and Company

Providing State of the Art Care for People With Obesity: Can We Break Free From the Status Quo?

PeerVoice // supported by an educational grant from Lilly |
Tuesday

Chair: Paolo Sbraccia (ITA) 07:45 – 07:48 Welcome and Introduction Paolo Sbraccia (ITA) 07:48 – 08:03 Reframing Obesity as a Chronic Disease Carel le Roux

New Class Worthy of a New Treatment Approach: How GIP/GLP-1 RA Tirzepatide Compares to GLP-1 RA Treatments

Eli Lilly and Company |
Monday

12:00 – 12:15 Welcome and Introduction to Tirzepatide Jennifer Green (USA) 12:15 – 12:30 What Do We Know About How Tirzepatide Compares to Semaglutide 1.0mg?

Should Faster Rapid-Acting Insulins be the standard for first line therapy?

Eli Lilly and Company |
Monday

Chair: Partha Kar (UK) 17:00 – 18:00 Should Faster Rapid-Acting Insulins be the standard for first line therapy? Matthias Weber (GER)Thomas Haak (GER)Partha Kar (UK)Emma

Addressing Weight Management in People with Type 2 Diabetes

Eli Lilly and Company |
Tuesday

Chair: Rachel Batterham (UK) 12:00 – 12:30 Addressing Weight Management in People with Type 2 Diabetes Alice Cheng (CAN) 3 October 2023 12:00 – 12:30

Connected Insulin Pens: Real World Experience

Eli Lilly and Company |
Wednesday

17:00 – 17:30 Connected Insulin Pens: Real World Experience Jens Kröger (GER)Eveleigh Nicholson (UK) 4 October 2023 17:00 – 17:30 CEST Spotlight Stage

Category: Eli Lilly and Company

Providing State of the Art Care for People With Obesity: Can We Break Free From the Status Quo? PeerVoice // supported by an educational grant from Lilly | Tuesday

New Class Worthy of a New Treatment Approach: How GIP/GLP-1 RA Tirzepatide Compares to GLP-1 RA Treatments Eli Lilly and Company | Monday

Should Faster Rapid-Acting Insulins be the standard for first line therapy? Eli Lilly and Company | Monday

Addressing Weight Management in People with Type 2 Diabetes Eli Lilly and Company | Tuesday

Connected Insulin Pens: Real World Experience Eli Lilly and Company | Wednesday

Providing State of the Art Care for People With Obesity: Can We Break Free From the Status Quo?

PeerVoice // supported by an educational grant from Lilly |
Tuesday

New Class Worthy of a New Treatment Approach: How GIP/GLP-1 RA Tirzepatide Compares to GLP-1 RA Treatments

Eli Lilly and Company |
Monday

Should Faster Rapid-Acting Insulins be the standard for first line therapy?

Eli Lilly and Company |
Monday

Addressing Weight Management in People with Type 2 Diabetes

Eli Lilly and Company |
Tuesday

Connected Insulin Pens: Real World Experience

Eli Lilly and Company |
Wednesday